Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct:54:77-83.
doi: 10.1016/j.ejmp.2018.06.635. Epub 2018 Oct 1.

Integral dose based inverse optimization objective function promises lower toxicity in head-and-neck

Affiliations

Integral dose based inverse optimization objective function promises lower toxicity in head-and-neck

Ivaylo B Mihaylov et al. Phys Med. 2018 Oct.

Abstract

Purpose: The voxels in a CT data sets contain density information. Besides its use in dose calculation density has no other application in modern radiotherapy treatment planning. This work introduces the use of density information by integral dose minimization in radiotherapy treatment planning for head-and-neck squamous cell carcinoma (HNSCC).

Materials and methods: Eighteen HNSCC cases were studied. For each case two intensity modulated radiotherapy (IMRT) plans were created: one based on dose-volume (DV) optimization, and one based on integral dose minimization (Energy hereafter) inverse optimization. The target objective functions in both optimization schemes were specified in terms of minimum, maximum, and uniform doses, while the organs at risk (OAR) objectives were specified in terms of DV- and Energy-objectives respectively. Commonly used dosimetric measures were applied to assess the performance of Energy-based optimization. In addition, generalized equivalent uniform doses (gEUDs) were evaluated. Statistical analyses were performed to estimate the performance of this novel inverse optimization paradigm.

Results: Energy-based inverse optimization resulted in lower OAR doses for equivalent target doses and isodose coverage. The statistical tests showed dose reduction to the OARs with Energy-based optimization ranging from ∼2% to ∼15%.

Conclusions: Integral dose minimization based inverse optimization for HNSCC promises lower doses to nearby OARs. For comparable therapeutic effect the incorporation of density information into the optimization cost function allows reduction in the normal tissue doses and possibly in the risk and the severity of treatment related toxicities.

Keywords: Dose; IMRT; Imaging; Integral dose; Mass; Optimization.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the optimization scheme used to perform the inverse planning with both – DV-and Energy-based optimization schemes. Both schemes utilized multi-stage dose reduction to the OARs used as dose-limiting structures.
Figure 2
Figure 2
Comparison of dose-volume-histograms (DVHs) and isodoses for a single case. The solid DVHs are derived from DV optimization, while the dashed lines are derived from Energy optimization. The DVHs for the different OARs are color-coded in the figure legend. On the right side of the figure there are comparisons of isodose plots in two orthogonal planes, where the far right column is with isodose plots from the Energy-based plan, while the column next to the DVHs plot represents the DV plan isodoses.

Similar articles

References

    1. Brizel DM, Vokes EE. Induction chemotherapy: to use or not to use? That is the question. Seminars in radiation oncology. 2009;19:11–6. - PubMed
    1. Bernier J. Current state-of-the-art for concurrent chemoradiation. Seminars in radiation oncology. 2009;19:3–10. - PubMed
    1. Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head & neck. 2001;23:579–89. - PubMed
    1. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol. 1996;14:838–47. - PubMed
    1. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. British journal of cancer. 1995;71:83–91. - PMC - PubMed

MeSH terms